Ciluprevir

Ciluprevir
Systematic (IUPAC) name
(1S,4R,6S,7Z,14S,18R)-14- {[(cyclopentyloxy)carbonyl]amino}-18-[(7-methoxy-2- {2-[(propan-2-yl)amino]-1,3-thiazol-4-yl}quinolin-4- yl)oxy]-2,15-dioxo-3,16- diazatricyclo[14.3.0.0{4,6}]nonadec-7-ene-4- carboxylic acid
Clinical data
Legal status
  • Investigational
Identifiers
CAS Number 300832-84-2
ATC code none
PubChem CID 9853710
ChemSpider 8029420
UNII 75C8DU40T0 YesY
ChEMBL CHEMBL297884
Chemical data
Formula C40H50N6O8S
Molar mass 774.93 g/mol

Ciluprevir is used experimentally in the treatment of hepatitis C. It is manufactured by Boehringer Ingelheim Pharma GmbH & Co. kg and developed under the research code of BILN-2061. It is targeted against NS2-3 protease.[1]

References

  1. Abbenante, G; Fairlie, DP (2005). "Protease inhibitors in the clinic". Medicinal chemistry 1 (1): 71–104. doi:10.2174/1573406053402569. PMID 16789888.


This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.